Incyte's royalty revenue from Eli Lilly's (NYSE:LLY) sales of rheumatoid arthritis drug Olumiant totaled $25.4 million in Q1, up 59% from the prior-year period.The company's net loss stemmed from primarily from an $805 million upfront payment to MorphoSys (NASDAQ:MOR) related to a licensing and collaboration deal for experimental blood cancer drug tafasitamab.